🇪🇺 JULUCA in European Union

EMA authorised JULUCA on 16 May 2018

Marketing authorisation

EMA — authorised 16 May 2018

  • Application: EMEA/H/C/004427
  • Marketing authorisation holder: ViiV Healthcare B.V.
  • Local brand name: Juluca
  • Indication: Juluca is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.
  • Status: approved

Read official source →

JULUCA in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Infectious Disease / Virology approved in European Union

Frequently asked questions

Is JULUCA approved in European Union?

Yes. EMA authorised it on 16 May 2018.

Who is the marketing authorisation holder for JULUCA in European Union?

ViiV Healthcare B.V. holds the EU marketing authorisation.